IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Lexington: Novo Nordisk A/S and Valo Health, Inc. have announced they have entered into an expanded agreement to discover and ...

Bagsværd, Denmark Friday, January 10, 2025, 11:00 Hrs [IST] ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

The stake comes alongside an agreement for Vancouver, Washington-based Absci to use AMD chips and software to power its drug discovery workloads, including a biologic drug design platform using ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic diseases, leveraging AI and extensive human datasets.

(Reuters) – Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human ...

Novo Nordisk and Valo plan to continue working closely together to derive novel insights from human genetic and longitudinal patient data at the intersection of obesity, type 2 diabetes, and ...